BSE Grants Listing Approval to Nexome Capital Markets for 19,20,000 Preferential Equity Shares

2 min read     Updated on 07 May 2026, 11:06 PM
scanx
Reviewed by
Jubin VScanX News Team
AI Summary

BSE Limited granted listing approval on May 07, 2026, to Nexome Capital Markets Limited for 19,20,000 equity shares of Rs. 10/- each, issued at a premium of Rs. 54/- per share on a preferential basis via warrant conversion. The shares, bearing distinctive numbers from 88,15,501 to 1,07,35,500, were allotted to both Promoter and Non-Promoter categories. Trading approval remains contingent on the company submitting requisite confirmations from NSDL/CDSL and, if applicable, a listing approval from NSE. The company must also apply for trading approval within seven working days of the listing approval date, as per SEBI's circular dated June 21, 2023.

powered bylight_fuzz_icon
39720987

*this image is generated using AI for illustrative purposes only.

Nexome Capital Markets Limited (formerly SMIFS Capital Markets Limited) has received listing approval from BSE Limited for 19,20,000 equity shares issued on a preferential basis through the conversion of warrants. The approval, communicated via BSE reference LOD/PREF/GB/FIP/195/2026-27 dated May 07, 2026, marks a significant step in the company's capital restructuring exercise under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Details of the Preferential Allotment

The newly listed shares carry a face value of Rs. 10/- each and were issued at a premium of Rs. 54/- per share. The allotment covers both Promoter and Non-Promoter categories, with the shares assigned distinctive numbers from 88,15,501 to 1,07,35,500. The table below summarises the key parameters of this preferential issue:

Parameter: Details
Number of Shares: 19,20,000 equity shares
Face Value: Rs. 10/- per share
Issue Premium: Rs. 54/- per share
Distinctive Numbers: 88,15,501 to 1,07,35,500
Allottee Category: Promoter and Non-Promoters
Basis of Issue: Preferential allotment via warrant conversion
BSE Approval Reference: LOD/PREF/GB/FIP/195/2026-27
Date of Approval: May 07, 2026

Regulatory Compliance Requirements

BSE has outlined several conditions that Nexome Capital Markets must fulfil before trading approval is granted for these shares. The exchange has directed the company to ensure compliance with Regulation 167 of SEBI (ICDR) Regulations and any subsequent SEBI directives. Additionally, in the event of a change exceeding two per cent of the total paid-up share capital, the company is required to file the shareholding pattern in XBRL mode as mandated under Regulation 31(1)(c) of SEBI LODR Regulations, 2015.

Conditions Precedent to Trading Approval

Trading approval for the aforementioned shares will be granted only upon the company submitting the following to BSE:

  • Listing approval from the National Stock Exchange of India Ltd. (if applicable)
  • Confirmation letters from NSDL/CDSL confirming the crediting of shares to respective beneficiary accounts or admission of capital to the depository system
  • Confirmation letters from NSDL/CDSL regarding lock-in of pre-preferential holding (if applicable)

Further, as per Schedule XIX of ICDR Regulations and SEBI circular no. SEBI/HO/CFD/PoD-2/P/CIR/2023/00094 dated June 21, 2023, Nexome Capital Markets is required to apply for trading approval to the stock exchange(s) within seven working days from the date of grant of listing approval. Non-compliance with this requirement will attract fines as specified in the said SEBI circular.

Company Communication

The disclosure was filed by Sanjana Gupta, Company Secretary cum Compliance Officer of Nexome Capital Markets Limited, in accordance with Regulation 30 of SEBI (LODR) Regulations, 2015. The BSE listing approval letter was issued by Marian D'souza, Assistant Vice President, and Gaurav Bajare, Deputy Manager, on behalf of BSE Limited. The company is headquartered at Vaibhav, 4th Floor, 4 Lee Road, Kolkata, West Bengal – 700020.

Historical Stock Returns for Nexome Capital Markets

1 Day5 Days1 Month6 Months1 Year5 Years
+3.89%+4.52%+26.61%-7.56%+36.14%+234.08%

How will the addition of 19,20,000 new equity shares impact Nexome Capital Markets' promoter shareholding pattern and potential dilution for existing shareholders?

What strategic initiatives or business expansion plans is Nexome Capital Markets likely to fund using the capital raised through this preferential allotment?

Will Nexome Capital Markets seek trading approval from the National Stock Exchange (NSE) in addition to BSE, and how might dual-listing affect the stock's liquidity?

like18
dislike

Nexome Capital Markets Converts 19.2L Warrants into Equity Shares

2 min read     Updated on 21 Apr 2026, 10:53 AM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Nexome Capital Markets Limited has successfully completed the conversion of 19,20,000 equity convertible warrants into equity shares following its board meeting held on April 20, 2026. The warrant holders exercised their right for conversion by paying the balance 75% of the issue price at Rs. 48/- per warrant, aggregating to Rs. 9,21,60,000/-. The total issue price per equity share stands at Rs. 64/-, comprising a face value of Rs. 10/- and a premium of Rs. 54/-. Pursuant to this conversion, the paid-up equity share capital of the company has increased to Rs. 10,73,55,000/-, consisting of 1,07,35,500 fully paid-up equity shares of Rs. 10/- each. The newly allotted shares will rank pari-passu with existing equity shares, and the company will make an application for listing and trading approval of these shares to the stock exchange.

powered bylight_fuzz_icon
37737787

*this image is generated using AI for illustrative purposes only.

Nexome Capital Markets Limited has successfully completed the conversion of 19,20,000 equity convertible warrants into equity shares following its board meeting held on April 20, 2026. The meeting, which commenced at 11:00 A.M. and concluded at 11:17 A.M., approved the allotment of 19,20,000 equity shares of face value Rs. 10/- each to existing warrant holders from both promoter and non-promoter categories.

Warrant Conversion Details

The warrant holders exercised their right for conversion by paying the balance 75% of the issue price at Rs. 48/- per warrant, aggregating to Rs. 9,21,60,000/-. Previously, 25% (Rs. 16/- per warrant) had been paid as warrant subscription price. The total issue price per equity share stands at Rs. 64/-, comprising a face value of Rs. 10/- and a premium of Rs. 54/-.

Category Allottee Warrants Converted Equity Shares Allotted Amount Received (Rs.)
Promoter Mr. Utsav Parekh 3,88,000 3,88,000 1,86,24,000
Non-Promoter Panchganga Advisors Pvt Ltd 3,85,000 3,85,000 1,84,80,000
Non-Promoter Monet Securities Pvt Ltd 3,85,000 3,85,000 1,84,80,000
Non-Promoter FORBES EMF 3,82,000 3,82,000 1,83,36,000
Non-Promoter Chivas Trading Pvt Ltd 3,80,000 3,80,000 1,82,40,000
Total 19,20,000 19,20,000 9,21,60,000

Capital Structure Impact

Pursuant to this conversion, the paid-up equity share capital of the company has increased to Rs. 10,73,55,000/-, consisting of 1,07,35,500 fully paid-up equity shares of Rs. 10/- each. The newly allotted shares will rank pari-passu with existing equity shares. The company will make an application for listing and trading approval of these shares to the stock exchange.

Post-Allotment Shareholding

The conversion has resulted in changes to the shareholding pattern. Mr. Utsav Parekh's holding increased to 5,32,300 shares (4.96%), while non-promoter entities including Panchganga Advisors Pvt Ltd (3.59%), Monet Securities Pvt Ltd (3.59%), FORBES EMF (3.56%), and Chivas Trading Pvt Ltd (3.56%) received significant stakes. The equity shares allotted pursuant to warrant conversion shall be subject to lock-in as per Chapter V of SEBI (ICDR) Regulations, 2018.

Historical Stock Returns for Nexome Capital Markets

1 Day5 Days1 Month6 Months1 Year5 Years
+3.89%+4.52%+26.61%-7.56%+36.14%+234.08%

How will the increased shareholding of non-promoter entities affect Nexome Capital Markets' corporate governance and strategic decision-making processes?

What impact might the Rs. 92.16 crore capital infusion have on Nexome's expansion plans and operational capabilities in the coming quarters?

Will the lock-in period restrictions under SEBI regulations create any liquidity constraints for the new shareholders in the near term?

like18
dislike

More News on Nexome Capital Markets

1 Year Returns:+36.14%